Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Nycomed/Centeon

This article was originally published in The Gray Sheet

Executive Summary

Nycomed/Centeon: Announce letter of intent under which Centeon will gain the exclusive rights to market Nycomed's TachoComb fibrin adhesive product to all countries outside of Europe, excluding Japan and certain other countries. Under terms of the deal, Centeon will make a down payment to Nycomed and contribute to TachoComb's worldwide development. Centeon also will fund and perform clinical development for the product in the U.S. and counties outside of Europe. TachoComb, a collagen fleece coated with a fibrin sealant, complements Centeon's fibrin sealant BeriPlast, both of which are used in tissue sealing and the control of bleeding. FDA currently is reviewing data from overseas trials of BeriPlast to determine whether the information is sufficient to support a premarket approval application or whether additional U.S. trials will be needed, Centeon says...
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT006523

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel